% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • johnpapas893 johnpapas893 Jun 9, 2013 10:24 AM Flag


    In view of the exceptional efficacy reported for CRd (carfilzomib, revlimid, and low-dose dexamethasone) for NDMM patients, it is likely that this combo will emerge as the standard front-line treatment. In the event of a ONXX take-over, Celgene could be as much a logical acquirer (and perhaps a more likely one) as Bayer.